Quick Answer
Kura Oncology, Inc. reported Research And Development Expense of $251.07 million for the year ending 2025.
- Kura Oncology, Inc. showed an increase of +47.7% in Research And Development Expense from 2024 to 2025.
- This data is from Kura Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $3.0 thousand | Q1 2015: $2.60 million | Q2 2015: $3.35 million | Q3 2015: $3.64 million | Q1 2019: $10.38 million | Q2 2019: $11.44 million | Q3 2019: $12.54 million | Q1 2020: $12.58 million | Q2 2020: $13.70 million | Q3 2020: $16.60 million | Q1 2021: $20.32 million | Q2 2021: $21.07 million | Q3 2021: $22.37 million | Q1 2022: $20.91 million | Q2 2022: $24.26 million | Q3 2022: $24.97 million | Q1 2023: $25.19 million | Q2 2023: $28.18 million | Q3 2023: $29.33 million | Q1 2024: $36.27 million | Q2 2024: $39.73 million | Q3 2024: $41.71 million | Q1 2025: $55.97 million | Q2 2025: $62.79 million | Q3 2025: $67.91 million.
- Over the full 9 years of available data (2017 to 2025), Kura Oncology, Inc.'s Research And Development Expense has grown by 850.1%.
- Historical annual values: Fiscal year 2025: $251.07 million | Fiscal year 2024: $169.97 million | Fiscal year 2023: $115.24 million | Fiscal year 2022: $92.81 million | Fiscal year 2021: $84.72 million | Fiscal year 2020: $60.40 million | Fiscal year 2019: $47.83 million | Fiscal year 2018: $46.79 million | Fiscal year 2017: $26.43 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: